NASDAQ to delist Rock Creek Pharmaceuticals stock

MANATEE—The NASDAQ Stock Market plans to delist Manatee County-based Rock Creek Pharmaceuticals on Thursday, according to a regulatory filing.

Rock Creek announced Monday that it will appeal NASDAQ’s decision to regain compliance. The stock market is delisting Rock Creek because it failed to maintain a minimum $1 bid price per share.

The company relocated this year to the offices of The Roskamp Institute at 2040 Whitfield Ave. and is now overseen by Roskamp’s Michael J. Mullan.

Rock Creek pulled its controversial Anatabloc product from the shelves earlier this year, but plans to announce findings of the drug’s main ingredient, anatabine, at a symposium this month.

Rock Creek, as RCPI, was trading at under 25 cents a share mid-day Tuesday.